Fitusiran Sodium

芬妥司兰钠

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameFitusiran Sodium
Drug Alias Name芬妥司兰费妥赛仑Qfitlia赛菲因ALN-AT3 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceAntithrombin-III inhibitors
TargetsAntithrombin-III
Therapy Area/IndicationsHemorrhageHemophilia BHemophilia A +[4] 
Global Approved IndicationsHemorrhageHemophilia BHemophilia A
Approved Indications in ChinaHemorrhageHemophilia BHemophilia A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/03/28
Country/TerritoryBelgiumBulgariaCanada +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiAlbany Molecular Research IncVetter Pharma-Fertigung Gmbh & Co Kg +[8] 
Inactive CompaniesN/A
Active IndicationsHemorrhageHemophilia BHemophilia A +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG